TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32041
Drug: Bunitrolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bunitrolol (10 mg i.v.)
Study: 32041
Drug: Oxprenolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxprenolol (10 mg i.v.)
Study: 21508090
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid supplementation (400 μg/d)
Study: 25725940
Drug: Oral immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral immunotherapy (OIT) with dehydrated egg white
Study: 21859559
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of PHY906 with irinotecan, 5‐fluorouracil (5‐FU), and leucovorin (LV)
Study: 17874238
Drug: Metformin (1,700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1,700 mg daily)
Study: 8694355
Drug: Placebo (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (20 ml 0.9% saline)
Study: 6755389
Drug: m‐Amsa (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: m‐Amsa (200 mg/m2 x 5 days) with Ara‐C (200 mg/m2 x 5 days)
Study: 6755389
Drug: m‐Amsa (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: m‐Amsa (200 mg/m2 x 5 days)
Study: 6755389
Drug: m‐Amsa (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: m‐Amsa (120 mg/m2 x 7 days) with Ara‐C (200 mg/m2 x 5 days)
Study: 6755389
Drug: m‐Amsa (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: m‐Amsa (high doses)
Study: 6755389
Drug: m‐Amsa (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: m‐Amsa (high doses) with Ara‐C (high doses)
Study: 6755389
Drug: Previous high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previous high doses of anthracyclins
Study: 28095813
Drug: Vocational rehabilitation
Normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vocational rehabilitation augmented with cognitive behaviour therapy (CBT)
Study: 18635693
Drug: MDMA (1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA (1.6 mg/kg b.wt.)
Study: 18635693
Drug: Pindolol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (20 mg)
Study: 15326236
Drug: Donepezil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (5 mg/day for 28 days, followed by 10 mg/day as per clinician's judgment)
Study: 11561261
Drug: Group I
Normalized name: Platelet group IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group I (air-buffered injections, n = 25)
Study: 11561261
Drug: Group II
Normalized name: Platelet group IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group II (conventional injections, n = 19)
Study: 31736381
Drug: Tadalafil 20
Normalized name: tadalafil 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 20 mg oral daily
Study: 31736381
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (no drug)
Study: 27285965
Drug: Fp MDPI
Normalized name: Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rIX-FP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fp MDPI 25 µg
Study: 27285965
Drug: Fp MDPI
Normalized name: Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rIX-FP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fp MDPI 50 µg
Study: 27285965
Drug: Fp MDPI
Normalized name: Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rIX-FP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fp MDPI 100 µg
Study: 27285965
Drug: Fp DPI
Normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fp DPI 100 µg
Study: 23507227
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (800 μg) and vitamin B(12) (1000 μg)
Study: 19338157
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy plus Xuefu Zhuyu Capsule (XFZYC)
Study: 18043171
Drug: Topical indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical indomethacin eyedrops
Study: 15138424
Drug: TCRFTA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCRFTA treatment (3 tongue treatments)
Study: 15138424
Drug: TCRFTA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCRFTA treatment (2 additional tongue and palate treatments)
Study: 10223915
Drug: Gatifloxacin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gatifloxacin alone (treatment A)
Study: 10223915
Drug: Gatifloxacin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gatifloxacin alone (treatment D)
Study: 10223915
Drug: Aluminum magnesium
Normalized name: Aluminum magnesium silicate
DrugBank: Aluminum acetate (DB14518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aluminum magnesium hydroxide 2 h before gatifloxacin (treatment B)
Study: 10223915
Drug: Aluminum magnesium
Normalized name: Aluminum magnesium silicate
DrugBank: Aluminum acetate (DB14518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aluminum magnesium hydroxide concomitant with gatifloxacin (treatment C)
Study: 10223915
Drug: Aluminum magnesium
Normalized name: Aluminum magnesium silicate
DrugBank: Aluminum acetate (DB14518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aluminum magnesium hydroxide 2 h after gatifloxacin (treatment E)
Study: 10223915
Drug: Aluminum magnesium
Normalized name: Aluminum magnesium silicate
DrugBank: Aluminum acetate (DB14518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aluminum magnesium hydroxide 4 h after gatifloxacin (treatment F)
Study: 7879932
Drug: Propofol 1.10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 1.10 mg/kg
Study: 7879932
Drug: Ketamine 0.39
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.39 mg/kg
Study: 7879932
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Propofol 0.63 mg/kg and Ketamine 0.21 mg/kg
Study: 7879932
Drug: Propofol 1.85
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 1.85 mg/kg
Study: 7879932
Drug: Ketamine 0.66
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.66 mg/kg
Study: 7879932
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Propofol 1.05 mg/kg and Ketamine 0.35 mg/kg
Study: 7879932
Drug: Propofol 1.61
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 1.61 mg/kg
Study: 7879932
Drug: Ketamine greater
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine greater than 0.85 mg/kg
Study: 7879932
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Propofol 1.50 mg/kg and Ketamine 0.50 mg/kg
Study: 7879932
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Propofol and Ketamine
Study: 7879932
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (Propofol, Ketamine, Combination)
Study: 30601452
Drug: TX‐001HR (17β‐estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: TX‐001HR (17β‐estradiol and progesterone combined in a single, oral, softgel capsule)
Study: 21934569
Drug: Patient-delivered partner
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-delivered partner therapy (PDPT)
Study: 19728711
Drug: Porridge with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Porridge with 4 g of beta-glucan
Study: 19728711
Drug: Granola with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granola with 4 g of beta-glucan
Study: 19728711
Drug: Bread with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bread with 4 g of beta-glucan
Study: 19728711
Drug: Pasta with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasta with 4 g of beta-glucan
Study: 17911186
Drug: Argatroban therapy
Normalized name: Argatroban
DrugBank: Argatroban (DB00278)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Argatroban therapy (N = 390; mean dose of 1.9 microg/kg/min for a mean 6 days)
Study: 17911186
Drug: Historical control
Normalized name: typhus, historical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Historical control therapy (N = 98)
Study: 17911186
Drug: Argatroban therapy
Normalized name: Argatroban
DrugBank: Argatroban (DB00278)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Argatroban therapy
Study: 15819461
Drug: Quinine capsule
Normalized name: quinine Oral Capsule
DrugBank: Quinine (DB00468)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quinine capsule
Study: 15819461
Drug: Quinine tablet
Normalized name: quinine Oral Tablet
DrugBank: Quinine (DB00468)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quinine tablet
Study: 15819461
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of quinine
Study: 9190868
Drug: Alprazolam 2
Normalized name: alprazolam 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam 2 mg/2 min i.v.
Study: 1539815
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine (0.2 mg/h) + epidural bupivacaine (10 mg/h)
Study: 1539815
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine (0.2 mg/h) alone
Study: 4002781
Drug: Muzolimine (M)
Normalized name: Coenzyme M
DrugBank: Muzolimine (DB13801)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muzolimine (M) 240 mg oral dose during dialysis (A)
Study: 4002781
Drug: Muzolimine (M)
Normalized name: Coenzyme M
DrugBank: Muzolimine (DB13801)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muzolimine (M) 240 mg oral dose after dialysis (B)
Study: 30656180
Drug: Omaveloxolone 160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omaveloxolone 160 mg/day
Study: 30656180
Drug: Omaveloxolone 160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omaveloxolone 160 mg/day in patients without pes cavus
Study: 22402059
Drug: α‐lipoic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: α‐lipoic acid (ALA) 600 mg/day
Study: 20002340
Drug: Massage therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy (20 minutes hands-on massage)
Study: 17383643
Drug: Adept (4%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adept (4% icodextrin solution)
Study: 17383643
Drug: LRS (lactated
Approvals — FDA: no, EMA: no, PMDA: no
Description: LRS (lactated Ringer's solution)
Study: 11384630
Drug: CEE 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE 0.3 mg/d plus MPA 1.5 mg/d
Study: 11384630
Drug: CEE 0.45
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE 0.45 mg/d plus MPA 1.5 mg/d
Study: 11384630
Drug: CEE 0.45
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE 0.45 mg/d plus MPA 2.5 mg/d
Study: 11384630
Drug: CEE 0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE 0.625 mg/d plus MPA 2.5 mg/d
Study: 23842013
Drug: Adjunctive agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive agents in placebo-controlled clinical trials
Study: 12483404
Drug: Commercially available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercially available amino acid solution (AA)
Study: 12483404
Drug: Lysine 25
Normalized name: lysine 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lysine 25 g
Study: 12483404
Drug: Lysine 50
Normalized name: lysine 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lysine 50 g
Study: 12483404
Drug: Lysine 75
Normalized name: aztreonam lysine 75 mg/mL INHALATION VIAL, NEBULIZER (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lysine 75 g
Study: 12483404
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 25 g of lysine plus 25 g of arginine (LysArg)
Study: 12483404
Drug: Fluid infusion
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid infusion alone (500, 1,000 or 2,000 ml of saline/glucose)
Study: 12483404
Drug: No amino
Normalized name: silk amino acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: No amino acid infusion (controls)
Study: 12483404
Drug: Lysine 75
Normalized name: aztreonam lysine 75 mg/mL INHALATION VIAL, NEBULIZER (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lysine 75 g (Lys75)
Study: 9561594
Drug: Intramuscular artemether
Normalized name: Artemether
DrugBank: Artemether (DB06697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular artemether (loading dose of 160 mg, followed by 80 mg daily for another 6 doses)
Study: 9561594
Drug: Quinine (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine (intravenous infusion of loading dose of 20 mg/kg, followed by 10 mg/kg q 8 hourly for 7 days)
Study: 3886401
Drug: Captopril 50
Normalized name: captopril 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 50 mg single dose
Study: 3886401
Drug: Captopril 50
Normalized name: captopril 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 50 mg three times daily for one week
Study: 3886401
Drug: Hydrochlorothiazide 50
Normalized name: hydrochlorothiazide 50 MG
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide 50 mg daily for one week
Study: 22787177
Drug: Insulin Glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin Glargine (GL)
Study: 9532991
Drug: Transcervical amnioinfusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcervical amnioinfusion of 800 mL saline at 15 mL per minute, followed by a maintenance infusion at 3 mL per minute
Study: 9532991
Drug: Transcervical amnioinfusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcervical amnioinfusion of 800 mL saline
Study: 2676650
Drug: Enterococcus SF68
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enterococcus SF68 (one capsule twice daily for prevention; three times daily for treatment)
Study: 2676650
Drug: Enterococcus SF68
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enterococcus SF68 (three times daily for treatment)
Study: 8383415
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg iron daily
Study: 29067756
Drug: Olmesartan medoxomil
Normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olmesartan medoxomil (OM)–based single-pill dual-combination therapy (OM+amlodipine/azelnidipine or hydrochlorothiazide)
Study: 19730391
Drug: Olmesartan monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan monotherapy
Study: 27318919
Drug: Dexmedetomidine (DEX)
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine (DEX) infusion at 0.5 μg/kg before induction and 0.2 μg/(kg×h) intraoperatively
Study: 19583073
Drug: Rectal acetaminophen
Normalized name: acetaminophen Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal acetaminophen 40 mg/kg
Study: 12228083
Drug: Internet-based curriculum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based curriculum on herbs and dietary supplements (10 weeks, 20 case-based modules)
Study: 9694050
Drug: Purified nucleohistone-binding
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified nucleohistone-binding antibodies from anti-DNA-depleted plasma IgG
Study: 9694050
Drug: Purified antibodies
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified antibodies from nephritis patient
Study: 9694050
Drug: Adsorption of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adsorption of purified antibodies with histone
Study: 28731778
Drug: Pharmacologic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacologic treatment algorithm
Study: 28731778
Drug: At least
Normalized name: Lovaza 1000 MG (at least 900 MG) Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: At least one psychiatric medication
Study: 25278336
Drug: Placebo therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo therapy (detuned ultrasound and shortwave therapy)
Study: 19390751
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg riboflavin daily for 28 days
Study: 15120716
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of stearidonic acid (1g/day) and gamma-linolenic acid (0.9g/day)
Study: 15120716
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of EPA with gamma-linolenic acid (GLA)
Study: 7235853
Drug: Weekly supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly supportive group meetings
Study: 20100408
Drug: 0.3% nifedipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3% nifedipine and 1.5% lidocaine ointment
Study: 20100408
Drug: 1.5% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5% lidocaine ointment alone
Study: 15817854
Drug: bIg (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: bIg (5 g)
Study: 10609394
Drug: Proximal adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Proximal adenosine infusion (108 to 3456 micrograms/min for 2 min)
Study: 10609394
Drug: Distal adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Distal adenosine infusion (108 to 3456 micrograms/min for 2 min)
Study: 8836079
Drug: Bone-patellar tendon-bone
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone-patellar tendon-bone autograft with Kennedy ligament augmentation device
Study: 8836079
Drug: Bone-patellar tendon-bone
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone-patellar tendon-bone autograft without Kennedy ligament augmentation device
Study: 1426214
Drug: Almitrine bismesylate
Normalized name: almitrine dimesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almitrine bismesylate (A), 50-100 mg daily
Study: 30672231
Drug: Conventional western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional western medication (Diazepam, 2.5 mg/day)
Study: 30672231
Drug: Placebo (starch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (starch capsule, once a day)
Study: 30672231
Drug: Conventional western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional western medication (Diazepam)
Study: 8704426
Drug: Placebo (starch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (starch capsule)
Study: 24842649
Drug: Bupropion (150/300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion (150/300 mg/day) + Duloxetine (60 to 120 mg/day)
Study: 24842649
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + Duloxetine (60 to 120 mg/day)
Study: 20461807
Drug: Perampanel 2
Normalized name: perampanel 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perampanel 2 mg
Study: 29157034
Drug: Pregabalin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (150 mg)
Study: 3722507
Drug: 1% topical
Normalized name: SSD 1% Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% topical minoxidil
Study: 16240515
Drug: Clindesse vaginal
Normalized name: Clindesse Vaginal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindesse vaginal cream (single dose)
Study: 16240515
Drug: Cleocin vaginal
Normalized name: Cleocin Vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cleocin vaginal cream (7 doses)
Study: 10948088
Drug: N(G)‐monomethyl‐L‐arginine (L‐NMMA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N(G)‐monomethyl‐L‐arginine (L‐NMMA)
Study: 10981082
Drug: ACE inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors (enalapril, captopril)
Study: 10981082
Drug: Beta-blockers (atenolol)
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers (atenolol)
Study: 10981082
Drug: Calcium-channel blockers
Normalized name: Channel catfish
DrugBank: Channel catfish (DB15548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium-channel blockers (long-acting nifedipine)
Study: 10981082
Drug: Diuretics (hydrochlorothiazide)
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretics (hydrochlorothiazide)
Study: 2351368
Drug: Cyproheptadine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproheptadine (6 mg)
Study: 2351368
Drug: DL Carnitine
Normalized name: DL-CARNITINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: DL Carnitine (1600 mg)
Study: 24090258
Drug: Topical decolonization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical decolonization with intranasal mupirocin twice daily plus 4% chlorhexidine gluconate body wash daily for 5 days before surgery
Study: 24090258
Drug: Oral antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antibiotics (cephalexin) with statim pre- and postoperative doses
Study: 22117991
Drug: Dexmedetomidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (1 μg/kg i.v. over 10 min followed by 0.2 - 0.7 μg/kg per h continuous i.v. infusion)
Study: 22117991
Drug: Remifentanil (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (0.8 - 1.2 μg/kg i.v. over 1 min followed by 0.05 - 0.1 μg/kg i.v. per min)
Study: 11327055
Drug: ePTFE combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: ePTFE combined with weekly repeated local application of minocycline ointment for 8 weeks after membrane placement
Study: 9623035
Drug: Regular surveillance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular surveillance using a simple questionnaire administered by non-professional personnel (cases)
Study: 7929726
Drug: Clonidine test
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine test to explore the ability of the pituitary to release growth hormone
Study: 7929726
Drug: Detection of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detection of anti‐granulosa cell auto‐antibodies in blood using an enzyme‐linked immunosorbent assay (ELISA)
Study: 3791153
Drug: Hydrazine sulfate
Normalized name: Hydrazine Sulfate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrazine sulfate (60 mg, 3 times/d)